HAMPHARMA
ActiveSummary
HAMPHARMA has been active since 1982 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €30,800 and a net result of €143,531. Equity remains stable across the filed financial years (±0.4% per year). Its solvency ranks better than 14% of 12,464 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Directors
Owners and capital
Owners
1 ownerChain of control
- Denayer Danielle
- HAMPHARMA
Highest known parent: Denayer Danielle. The sources do not say who stands above it.
Owners 1
- Denayer Danielleparent99.6%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.